Brief Report

BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects

Ilaria Vicenti 1,*, Francesca Gatti 2, Renzo Scaggiante 3, Adele Boccuto 1, Daniela Zago 2, Monica Basso 2, Filippo Dragoni 3,*, Saverio Giuseppe Parisi 2,*,† and Maurizio Zazzi 1,†

1 Department of Medical Biotechnologies, University of Siena, Viale Bracci, 16, 53100 Siena, Italy; vicenti@unisi.it (I.V.); boccuto2@student.unisi.it (A.B.); dragoni16@student.unisi.it (F.D.); maurizio.zazzi@unisi.it (M.Z.)
2 Department of Molecular Medicine, University of Padova, Via Gabelli, 63, 35100 Padova, Italy; francesca.gatti@asst-garda.it (F.G.); daniela.zago.3@studenti.unipd.it (D.Z.); monica.basso@unipd.it (M.B.)
3 Belluno Hospital, Viale Europa, 22, 32100 Belluno, Italy; renzo.scaggiante@aulss1.veneto.it
* These authors contributed equally to this manuscript.
† These authors contributed equally to this manuscript.

Abstract: We aimed to investigate neutralizing antibody titers (NtAbT) to the P.1 and B.1 SARS-CoV-2 variants in a cohort of healthy health care workers (HCW), including 20 previously infected individuals tested at baseline (BLinf, after a median of 298 days from diagnosis) and 21 days after receiving one vaccine dose (D1inf) and 15 uninfected subjects tested 21 days after the second-dose vaccination (D2uninf). All the subjects received BNT162b2 vaccination. D1inf NtAbT increased significantly with respect to BLinf against both B.1 and P.1 variants, with a fold-change significantly higher for P.1. D1inf NtAbT were significantly higher than D2uninf NtAbT against B.1 and P.1. NtAbT against the two strains were highly correlated. P.1 NtAbT were significantly higher than B.1 NtAbT. This difference was significant for post-vaccination sera in infected and uninfected subjects. A single-dose BNT162b2 vaccination substantially boosted the NtAb response to both variants in the previously infected subjects. NtAb titers to B.1 and P.1 lineages were highly correlated, suggesting substantial cross-neutralization. Higher titers to the P.1 than to the B.1 strain were driven by the post-vaccination titers, highlighting that cross-neutralization can be enhanced by vaccination.

Keywords: SARS-CoV-2 vaccination; neutralizing antibodies; live virus neutralization; B.1 variant; P.1 variant; previously infected and uninfected subjects; health care workers

1. Introduction

Administration of a variety of SARS-CoV-2 vaccines is proceeding at different paces in diverse geographical areas. The key question on the rate and durability of protection with the different vaccines has been further complicated by the emergence of fast-spreading variants, including the United Kingdom (B.1.1.7, alpha), South Africa (B.1.351, beta), and Brazil (P.1, gamma) lineages [1]. Indeed, SARS-CoV-2 variants escaping vaccine-induced protection have the potential to re-ignite virus transmission even in regions with optimal vaccine coverage. The first approved SARS-CoV-2 vaccines BNT162b2 and mRNA1273 have been administered to millions of people, and both are based on mRNA coding for the full-length prefusion spike glycoprotein derived from the original SARS-CoV-2 strain (lineage B). A series of small studies based on different methods for assessment of virus-neutralizing antibody (NtAb) have shown that the B.1.1.7 (alpha) variant is effectively neutralized by convalescent sera from individuals recovering from first-wave wild-type SARS-CoV-2 infection as well as by sera from BNT162b2 or mRNA1273 vaccine recipients, while neutralization of the B.1.351 (beta) variant appears to be weaker, although generally still robust [2–6].
Fewer and less consistent data have been obtained with the P.1 (gamma) variant. The P.1 (gamma) variant was identified for the first time in the city of Manaus, North Brazil, in December 2020 and further in passengers from Brazil tested at an airport nearby Tokyo [7]. Variant spike protein substitutions are L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, and T1027I [8]. P.1 (gamma) was defined a variant of concern because it shared mutations with other variants of concern and because of its transmissibility: a two-category dynamical model integrating genomic and mortality data estimated that P.1 (gamma) could be between 1.7 and 2.4 times more transmissible in Manaus than non-P.1 lineages [9]; moreover P.1 (gamma) led to re-infection after a previous SARS-CoV-2 infection [10]. In another cohort of individuals who received two doses of BNT162b2 or mRNA1273 vaccines, NtAb responses were also significantly decreased to the P.1 (gamma) strain, particularly in BNT162b2 vaccine recipients [2]. Interestingly, the six vaccinees reporting prior COVID-19 had high NtAb titers to most variants and exhibited substantial cross-neutralization even to the distantly related 2002–2003 SARS-CoV and pre-emergent bat-derived WIV1-CoV. This suggests that vaccination following prior infection substantially increases the breadth of cross-reactive NtAb. Similarly, Lustig et al. showed that one BNT162b2 vaccine dose increased neutralizing activity by 2 orders of magnitude against all variants tested (B.1.1.7 or alpha, B.1.351 or beta, and P.1 or gamma) in all of six previously infected health care workers (HCW) analyzed before and after vaccination [11].

2. Materials and Methods

To further investigate the role of BNT162b2 vaccination in NtAb titers to the P.1 variant, we studied a cohort of healthy HCW, including 20 previously infected individuals tested at baseline (BL inf) and 21 days after receiving one vaccine dose (D1 inf) and 15 uninfected subjects tested 21 days after the second-dose vaccination (D2 uninf). The previously infected group had a median age of 46 (37–52) years, included 70% females, had a laboratory diagnosis of SARS-CoV-2 infection in the Veneto region during the first outbreak in March–April 2020 when the original B.1 lineage was highly prevalent, and received a single-dose vaccination after a median of 298 (283–304) days from diagnosis. All the previously infected subjects enrolled were asymptomatic or had mild disease [12]: the diagnosis was made because of clinical suspicion or in the context of the hospital surveillance program. Eight of the twenty patients had mild disease, all with fever. A detailed description is reported in Table 1.

Table 1. Description of signs and/or symptoms of the health care workers with mild COVID-19.

| Patients | Age (Years) | Fever | Cough | Asthenia |
|----------|-------------|-------|-------|---------|
| Pt 1     | 46          | x     | x     |         |
| Pt 2     | 48          | x     | x     | x       |
| Pt 3     | 32          | x     |       | x       |
| Pt 4     | 47          | x     |       |         |
| Pt 5     | 49          | x     |       |         |
| Pt 6     | 54          | x     | x     |         |
| Pt 7     | 45          |       | x     |         |
| Pt 8     | 44          |       |       |         |

The uninfected group included HCW from the same region, had a median age of 49 (30–58) years with 67% females, and completed the two-dose vaccination schedule in January–February 2021. NtAb to the live virus belonging to the B.1 and P.1 lineages, as assessed by NGS (submitted to GISAID, accession number EPI_ISL_2472918 for P.1 and EPI_ISL_2472896 for B.1), were titrated in duplicate by testing two-fold serial dilutions of sera with 100 TCID50 of the corresponding SARS-CoV-2 strain in Vero E6 cells with automated measurement of cell viability by the Cell-titer Glo 2.0 system in a GloMax Discover luciferase plate reader (Promega, Madison, WI, USA) [13–15]. The NtAb titer (ID50) was defined as the reciprocal value of the sample dilution that showed a 50% protection from the virus-induced cytopathic effect. Each run included an uninfected
control, an infected control, and the virus back-titration to confirm the virus inoculum. NtAb titers were expressed as median (IQR), and the non-parametric Wilcoxon signed-rank sum test and Mann–Whitney test were used to analyze changes in paired and unpaired data, respectively. Spearman analysis was used to measure the correlation between NtAb titers to the two viral strains. Analyses were run in IBM SPSS Statistics, version 20 (IBM Corp., Armonk, NY, USA) and all \( p \)-values were 2-sided.

Written informed consent was obtained from all the HCW to be enrolled in a neutralizing antibody (NtAb) follow-up study, as approved by the comitato per la sperimentazione clinica di Treviso e Belluno (protocol code 812/2020).

3. Results

In the previously infected patient group, D1\textsubscript{inf} NtAb titers increased significantly with respect to BL\textsubscript{inf} against both the B.1 (median values 1706 (993–3186) vs. 38 (16–67); \( p < 0.001 \)) and the P.1 (median values 4087 (3324–5053) vs. 66 (30–129); \( p < 0.001 \)) variant, with a fold-change significantly higher for the P.1 variant vs. the B.1 wild type (94 (29–134) vs. 44 (15–70); \( p = 0.03 \)).

At 20 days post-vaccination, D1\textsubscript{inf} NtAb titers were significantly higher than D2\textsubscript{uninf} NtAb titers against both the B.1 (median values 1706 (993–3186) vs. 190 (119–302); \( p < 0.0001 \)) and the P.1 (median values 4087 (3324–5053) vs. 288 (147–904) \( p < 0.0001 \)) variant. Overall, NtAb titers against the two strains were highly correlated (rho = 0.924, \( p < 0.001 \)). However, P.1 NtAb titers were significantly higher with respect to B.1 NtAb titers (median 394 (73–368) vs. 225 (75–1227), \( p < 0.001 \)). Interestingly, this difference was significant for post-vaccination data in infected and uninfected subjects (D1\textsubscript{inf}: 4087 (3227–5125) vs. 1706 (993–3186), \( p < 0.001 \); D2\textsubscript{uninf} 288 (147–904) vs. 190 (119–302), \( p = 0.02 \)) but not for BL\textsubscript{inf} (66 (29–130) vs. 38 (16–167), \( p = 0.13 \)) (Figure 1).

Figure 1. Neutralizing antibody titers to the original B.1 lineage and the P.1 SARS-CoV-2 variant in 20 infected subjects tested at baseline (BL\textsubscript{inf}) and 21 days following single-dose BNT162b2 vaccination (D1\textsubscript{inf}) and in 15 uninfected subjects tested 21 days following second-dose BNT162b2 vaccination (D2\textsubscript{uninf}). Data are reported as individual ID\textsubscript{50} values and as median value at each study time. The same symbols indicate the same subjects at different time points. Asterisks indicate significance levels: *, \( p < 0.05 \), ***, \( p < 0.001 \).

Outcomes of studies focusing on P.1 and BNT162b2 are summarized in Table 2.
Table 2. Description of the studies focusing on the neutralizing antibody response in subjects vaccinated with BNT162b2 mRNA COVID-19 vaccine.

| N | Authors and Year of Publication | Study Population | Country | Total Number of Subjects Enrolled | History of Natural SARS-CoV-2 Infection | Study Points | Neutralizing Antibody Method | SARS-CoV-2 Strains Tested Other Than P.1 | Main Results |
|---|---------------------------------|------------------|---------|-----------------------------------|----------------------------------------|--------------|-------------------------------|------------------------------------------|-------------|
| 1 | Zani et al., 2021 [16]          | Volunteers       | Italy   | 37                                | No                                    | Between 10 and 20 days after administration of second dose of vaccine | Cytopathic-effect-based assay using authentic viruses isolated in Italy | B.1, B.1.1.7, B.1.351, B.1.525 | All the serum samples efficiently neutralized the SARS-CoV-2 B.1 lineage and all the viral variants. As compared with neutralization of the SARS-CoV-2 B.1 lineage, neutralization of the SARS-CoV-2 P.1 lineage was robust but significantly lower. |
| 2 | Gidari et al., 2021 [17]        | Vaccinated health care workers, candidates as hyper-immune plasma donors, patients with ascertained SARS-CoV-2 P.1 infection | Italy   | 202                               | Yes (n = 112) and no (n = 90)           | Median of 16 days after the second dose in vaccinated health care workers, median of 67 days after diagnosis of infection in candidates as hyper-immune plasma donors, median of 21 days after diagnosis of P.1 infection | In-house microneutralization assay | 20A.EU1, B.1.1.7 | B.1.1.7 and P.1 were less efficiently neutralized by convalescent wild-type infected serums if compared to the 20A.EU1 strain. BNT162b2 vaccine-elicited human sera showed equivalent neutralization potency against the B.1.1.7 variant, but it was significantly lower against the P.1 variant. Convalescent P.1 patients showed an important reduction in neutralizing antibodies against 20A.EU1 and B.1.1.7. |
Table 2. Cont.

| N  | Authors and Year of Publication | Study Population | Country | Total Number of Subjects Enrolled | History of Natural SARS-CoV-2 Infection | Study Points | Neutralizing Antibody Method | SARS-CoV-2 Strains Tested Other Than P.1 | Main Results |
|----|---------------------------------|------------------|---------|----------------------------------|----------------------------------------|--------------|------------------------------|------------------------------------------|-------------|
| 3  | Barros-Martins et al., 2021 [18] | Health care professionals vaccinated with first dose of AstraZeneca’s ChAdOx1-nCov-19 (ChAd) and with second dose of the same vaccine or of BNT162b2 | Germany | 87 | No | Before and 3 weeks after booster with ChAd or with BNT162b2 | Enzyme-linked-immunosorbent-assay-based surrogate virus neutralization test | Wuhan, B.1.1.7, B.1.351 | Both vaccines boosted prime-induced immunity, and BNT162b2 induced high titers of neutralizing antibodies against the B.1.1.7, B.1.351, and P.1 variants. |
| 4  | Lustig et al., 2021 [19]        | Healthy health care workers | Israel | 36 | No | 1 month following receipt of second vaccine dose | Microneutralization assays | Sub-lineage B.1 (hCoV-19/Israel/CVL-45526-ngs/2020), alpha (hCoV-19/Israel/CVL-46879-ngs/2020), beta (hCoV-19/Israel/CVL-2557-ngs/2020), and delta sample 1 (S1, hCoV-19/Israel/CVL-12804/2021 and S2, hCoV-19/Israel/CVL-12806/2021) | There was significant fold-change reduction in neutralizing titres compared with the original virus for gamma (P.1), beta (B.1.351), and delta variants. The reduction in the alpha (B.1.1.7) variant was not significant. |
| N | Authors and Year of Publication | Study Population | Country | Total Number of Subjects Enrolled | History of Natural SARS-CoV-2 Infection | Study Points | Neutralizing Antibody Method | SARS-CoV-2 Strains Tested Other Than P.1 | Main Results |
|---|---------------------------------|-----------------|---------|----------------------------------|----------------------------------------|-------------|-----------------------------|----------------------------------------|-------------|
| 5 | Collier et al., 2021 [20]       | Community participants or health care workers | United Kingdom | 140 | Yes (n = 10) and no (n = 130) | 3 to 12 weeks after first of dose vaccine and again 3 weeks after second dose of vaccine | Pseudotyped virus neutralization assays | Wild type, B.1.1.7, B.1.351 | Sera from participants above 80 showed lower neutralization potency against the B.1.1.7, B.1.351, and P.1. variants of concern (VOC) than against the wild-type virus and were more likely to lack any neutralization against VOC following the first dose. However, following the second dose, neutralization against VOC was detectable regardless of age. |
| 6 | Stankov et al., 2021 [21]       | Health care professionals | Germany | 231 | Yes (n = 83) and no (n = 148) | Mean of 17.6 days after first dose and a mean of 21 days after second dose | ePass Neutralization Antibody Detection kit (GenScript) | SARS-CoV-2 wild type, B.1.1.7, B.1.351 | A single vaccine dose may frequently fail to induce a measurable neutralizing antibody response. |
| 7 | Leier et al., 2021 [22]         | Participants | United States | 30 | Yes (n = 10), and no (n = 20) | Immediately after receiving first dose of vaccine and at least 14 days after second vaccine dose | Focus reduction neutralization test | B.1.1.7, B.1.351, USA257 WA1/2020 | Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees against every variant tested: B.1.1.7, B.1.351, P.1, and original SARS-CoV-2. |
| N  | Authors and Year of Publication | Study Population | Country | Total Number of Subjects Enrolled | History of Natural SARS-CoV-2 Infection | Study Points | Neutralizing Antibody Method | SARS-CoV-2 Strains Tested Other Than P1 | Main Results                                                                                                                                 |
|----|--------------------------------|------------------|---------|----------------------------------|--------------------------------------|-------------|----------------------------|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| 8  | Anichini et al., 2021 [23]    | Health care workers | Italy   | 60                               | No                                   | 30 days after second dose of vaccine | Microneutralization assay           | Native Wuhan, B.1.1.7, B.1.351         | The neutralizing antibody titers elicited against the wild-type strain showed a slight decrease versus the P1 lineage and a significant decrease to the B.1.351 lineage. No significant differences were found in comparison with the B.1.1.7 lineage. |
| 9  | Caniels et al., 2021 [24]     | Convalescent COVID-19 patients and vaccinated health care workers | Netherlands | 119                              | Yes \((n = 69)\) and no \((n = 50)\) | Sera of SARS-CoV-2-infected adults collected 4 to 6 weeks after symptom onset, sera collected 4 weeks after second dose of vaccine in 50 health care workers | Pseudovirus neutralization assay, authentic virus neutralization assay | Wild type, B.1.1.7, B.1.351 | Substantial neutralizing activity was present against the WT virus in 96% of convalescent patients irrespective of hospitalization and in all vaccine recipients. There was a marked and significant reduction in serum ability to neutralize pseudovirus variants of concern. For all three groups, the difference was most apparent against B.1.351. |
Table 2. Cont.

| N  | Authors and Year of Publication | Study Population | Country       | Total Number of Subjects Enrolled | History of Natural SARS-CoV-2 Infection | Study Points | Neutralizing Antibody Method | SARS-CoV-2 Strains Tested Other Than P.1 | Main Results |
|----|---------------------------------|------------------|---------------|----------------------------------|----------------------------------------|--------------|-------------------------------|-----------------------------------------|-------------|
| 10 | Dejnirattisai et al., 2021 [25] | Participants     | United Kingdom| 59                               | Yes (n = 34) and no (n = 25)           | Serum collected 4–14 days following second dose of vaccine, samples collected 4-9 weeks following infection in previously infected | Live virus neutralization test | Victoria (SARS-CoV-2/human/AUS/VIC01/2020), B.1.1.7, B.1.351 | In convalescent samples, P.1 mean neutralization titres were reduced compared to Victoria. This reduction was similar to B.1.1.7 and considerably less than B.1.351. In vaccine serum, mean neutralization titres against P.1 were reduced to the Victoria virus. Neutralization titres against P.1 were similar to those against B.1.1.7, with a significant reduction against B.1.351. |
| 11 | Garcia-Beltran et al., 2021 [2] | Participants     | USA           | 30                               | No (except one suspected case)        | Serum collected 7–32 days following second vaccine dose | Lentivirus-vector pseudovirus neutralization test | Wild type, B.1.1.7, B.1.1.298, B.1.429, P.2, B.1.351 | There was a decrease in neutralization relative to the wild type for B.1.1.7, for B.1.1.298, for B.1.429, for P.1, and for B.1.351. |
4. Discussion

The NtAb response to SARS-CoV-2 vaccination is being increasingly investigated to determine the impact of virus variability on vaccine efficacy. The P.1 variant is of particular concern due to the resurgence of high infection rates in Brazilian areas with supposedly large prevalence of first-wave infection [26]. Various previous studies have shown that vaccination of uninfected subjects with B lineage mRNA vaccines elicits lower but measurable NtAb titers to the P.1 variant compared to the other variants [2]. In our group of 15 uninfected BNT162b2 vaccinees, the NtAb response to the P.1 variant was not decreased, or even higher, compared to the original B.1 lineage virus. Notably, in the 20 previously infected subjects included in our study, single-dose vaccination substantially boosted the NtAb response to both variants tested, supporting the data reported by Lustig et al. in six analogous patients whose sera had high NtAb titers to the B.1.1.7, B.1.351, and P.1 lineages [11]. This may support the recommendation for vaccinating previously infected patients [27]. However, the increased titer and breadth of NtAb could simply reflect the expected secondary immune response without conferring stronger immunity to secondary infection.

The NtAb titer after a single vaccine dose in previously infected subjects was higher than NtAb titer in uninfected HCW after a complete vaccination schedule: this result is in accord with data published by Mazzoni et al. [28], who had uninfected subjects tested after a shorter (7 days after the second dose) and a longer (50 days from the first vaccine dose) interval than ours (21 days after the second dose). Conversely, comparable titers were reported in the study by Gobbi et al. [29] and in that by Ebinger et al. [30]: possible explanations for the different results may be the low numerosity (15 subjects) for the first one and the racial distribution for the second one (white people were about 50%).

The more intense humoral response in SARS-CoV-2-exposed subjects seemed not related to the vaccine type administered: the anti-receptor-binding domain of SARS-CoV-2 spike protein antibody titers was significantly higher in HCWs with a previous natural infection 4 weeks after the second dose of inactivated SARS-CoV-2 vaccine (CoronaVac) [31]. Of note, we should take into account the risk of an excess of immune activation, followed by switch-off of the response for antigen exhaustion: this mechanism may explain the reduced antibody response after the second vaccine dose in subjects with a previous infection [28,32]. Finally, the extreme heterogeneity of the methods used in the different studies, commercial or in-house methods, using recombinant viruses or authentic viral strains, as in our case, often make this evidence poorly comparable.

NtAb titers to B.1 and P.1 lineages were highly correlated in the whole case file. Intriguingly, paired analysis revealed higher titers to the P.1 than to the B.1 strain. This overall effect was driven by the post-vaccination titers, highlighting that. Interestingly, as recently published, patients infected with the B.1.351.V2 South African variant had higher NtAb titers to the related B.1.351.V3 variant than to the infecting B.1.351.V2 strain [33] and uninfected recipients of the BNT162b2 vaccine responded better to a recombinant virus mimicking the B.1.1.7 variant than to the vaccine strain [6]. These data show that SARS-CoV-2 variants may be well controlled following natural or artificial immunization with a different variant [34]. The characteristics of the antigenicity of the P.1 variant are not completely known [35]: this fact and the different study designs, viral components tested (strain isolated from a clinical sample or generated mutant, as in Chang et al. [36]), and commercial or in-house methods used to evaluate different kinds of antibody titers may explain the multifaceted response to the P.1 variant with respect to other SARS-CoV-2 strains. Gidari et al. [17] described a post-vaccinal NtAb titer to B1 and P1 specular to ours, and sera from vaccinated individuals showed a significant loss of neutralizing activity against P1 but the impact was lower than that against B.1.351 [24,25,37]: these data underline the need to include SARS-CoV-2 viral sequencing of PCR-positive COVID-19 subjects in the diagnostic workflow because variant diffusion may reduce vaccine efficacy.
The strength of our work lies in the homogeneity of the cohort, in the history of mild or asymptomatic infection, in the long interval from infection to pre-vaccine evaluation, and in the use of two authentic viral isolates into a classical neutralization assay. It must be noted that a number of factors can complicate the interpretation of NtAb data, including ethnicity, use of different test virus strains, and the NtAb titration technology, particularly the live virus vs. pseudovirus or spike recombinant format.

While most studies appear to support a clinically valuable breadth of the NtAb response irrespective of the infecting or vaccine virus variant, surveillance as well as development of reference isolates and technical standards remain mandatory to manage the impact of ongoing SARS-CoV-2 variability on the control of infection.

**Author Contributions:** Conceptualization, S.G.P.; methodology, M.Z., I.V., A.B. and F.D.; validation, I.V., S.G.P. and M.Z.; formal analysis, M.Z. and I.V.; resources, F.G. and R.S.; data curation, S.G.P.; writing—original draft preparation, M.Z. and S.G.P.; visualization, I.V.; supervision, S.G.P.; project administration, D.Z. and M.B.; funding acquisition, S.G.P. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the University of Padova (grant nos. DOR-2019 and DOR-2020 to S.G.P.).

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the comitato per la sperimentazione clinica di Treviso e Belluno (protocol code 812/2020).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Raw data can be made available by the corresponding author upon reasonable request.

**Acknowledgments:** We thank Alessia Lai (University of Milan) and Daniela Francisci (University of Perugia) for providing the anonymized B.1 and P.1 isolates used in the study.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

**References**

1. McCormick, K.D.; Jacobs, J.L.; Mellors, J.W. The emerging plasticity of SARS-CoV-2. *Science* 2021, 371, 1306–1308. [CrossRef]
2. Garcia-Beltran, W.F.; Lam, E.C.; St Denis, K.; Ntito, A.D.; Garcia, Z.H.; Hauser, B.M.; Feldman, J.; Pavlovic, M.N.; Gregory, D.J.; Poznansky, M.C.; et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell* 2021, 184, 2372–2383. [CrossRef] [PubMed]
3. Kuzmina, A.; Khalaila, Y.; Voloshin, O.; Keren-Naus, A.; Boehm-Cohen, L.; Raviv, Y.; Shemer-Avni, Y.; Rosenberg, E.; Taube, R. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. *Cell Host. Microbe* 2021, 29, 522–528.e2. [CrossRef]
4. Liu, Y.; Liu, J.; Xia, H.; Zhang, X.; Fontes-Garfias, C.R.; Swanson, K.A.; Cai, H.; Sarkar, R.; Chen, W.; Cutler, M.; et al. Neutralizing Activity of BNT162b2-Elicited Serum. *N. Engl. J. Med.* 2021, 384, 1466–1468. [CrossRef]
5. Planas, D.; Bruel, T.; Grzelak, L.; Guivel-Benhassine, F.; Staropoli, I.; Porrot, F.; Planchais, C.; Buchrieser, J.; Rajah, M.M.; Bishop, E.; et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *Nat. Med.* 2021, 27, 917–924. [CrossRef] [PubMed]
6. Xie, X.; Liu, Y.; Liu, J.; Zhang, X.; Zou, J.; Fontes-Garfias, C.R.; Xia, H.; Swanson, K.A.; Cutler, M.; Cooper, D.; et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat. Med.* 2021, 27, 620–621. [CrossRef] [PubMed]
7. Vasireddy, D.; Vanaparthy, R.; Mohan, G.; Malayala, S.V.; Atluri, P. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? *J. Clin. Med. Res.* 2021, 13, 317–325. [CrossRef]
8. US COVID-19 Cases Caused by Variants. Centers for Disease Control and Prevention. Available online: https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html (accessed on 14 August 2021).
9. Faria, N.R.; Mellan, T.A.; Whittaker, C.; Claro, I.M.; Candido, D.D.S.; Mishra, S.; Crispim, M.A.E.; Sales, F.C.S.; Hawryluk, I.; McCrone, J.T.; et al. Genomics and epidemiology of the P1 SARS-CoV-2 lineage in Manaus, Brazil. *Science* 2021, 372, 815–821. [CrossRef] [PubMed]
1. Romano, C.M.; Felix, A.C.; Paula, A.V.; Jesus, J.G.; Andrade, P.S.; Cândido, D.; Oliveira, F.M.; Ribeiro, A.C.; Silva, F.C.D.; Inemami, M.; et al. SARS-CoV-2 reinfection caused by the P.1 lineage in Araraquara city, Sao Paulo State, Brazil. Rev. Inst. Med. Trop. Sao Paulo 2021, 63, e36. [CrossRef] [PubMed]

2. Lustig, Y.; Nemet, I.; Kliker, L.; Zuckerman, N.; Yishai, R.; Alroy-Preis, S.; Mendelson, E.; Mandelboim, M. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2. N. Engl. J. Med. 2021, 384, 2453–2454. [CrossRef] [PubMed]

3. National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available online: https://www.covid19treatmentguidelines.nih.gov/ (accessed on 14 August 2021).

4. Vicenti, I.; Gatti, F.; Scaggiante, R.; Boccuto, A.; Zago, D.; Basso, M.; Dragoni, F.; Zazzi, M.; Parisi, S.G. Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in healthcare workers recovering from asymptomatic or mild natural SARS-CoV-2 infection. Int. J. Infect. Dis. 2021, 108, 176–178. [CrossRef]

5. Vicenti, I.; Gatti, F.; Scaggiante, R.; Boccuto, A.; Zago, D.; Basso, M.; Dragoni, F.; Zazzi, M.; Parisi, S.G. Time course of neutralizing antibody in healthcare workers with mild or asymptomatic COVID-19 infection. Open. Forum. Infect. Dis. 2021, in press. [CrossRef]

6. Barros-Martins, J.; Hammerschmidt, S.I.; Cossmann, A.; Odak, I.; Stankov, M.V.; Morillas Ramos, G.; Dopfer-Jablonka, A.; Heidemann, A.; Ritter, C.; Friedrichsen, M.; et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat. Med. 2021. [CrossRef]

7. Lustig, Y.; Zuckerman, N.; Nemet, I.; Atari, N.; Kliker, L.; Regev-Yochay, G.; Sapir, E.; Mor, O.; Alroy-Preis, S.; Mendelson, E.; et al. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNtech/Pfizer) vaccination in health care workers, Israel. Eurosurveillance 2021, 26, 2100557. [CrossRef]

8. Collier, D.A.; Ferreira, I.A.T.M.; Kotagiri, P.; Dattir, R.P.; Lim, E.Y.; Touizer, E.; Meng, B.; Abdullahi, A. CTTIID-NIHR BioResource COVID-19 Collaboration.; Elmer A.; et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 2021, 596, 417–422. [CrossRef] [PubMed]

9. Stankov, M.V.; Cossmann, A.; Bonifacius, A.; Dopfer-Jablonka, A.; Ramos, G.M.; Gödecke, N.; Scharff, A.Z.; Happle, C.; Boeck, A.L.; Tran, A.T.; et al. Humoral and cellular immune responses against SARS-CoV-2 variants after single BNT162b2 vaccination. Clin. Infect. Dis. 2021, 63, 4175. [CrossRef] [PubMed]

10. Leier, H.C.; Bates, T.A.; Lyski, Z.L.; McBride, S.K.; Lee, D.X.; Coulter, F.J.; Goodman, J.R.; Lu, Z.; Curlin, M.E.; Messer, W.B.; et al. Previously infected vaccinees broadly neutralize SARS-CoV-2 variants. medRxiv 2021. [CrossRef] [PubMed]

11. Anichini, G.; Terrosi, C.; Gori Savellini, G.; Gandolfo, C.; Franchi, F.; Cusi, M.G. Neutralizing antibody response of vaccinees to SARS-CoV-2 infection and One Dose of BNT162b2. N. Engl. J. Med. 2021, 384, 2453–2454. [CrossRef] [PubMed]

12. Marot, S.; Malet, I.; Leducq, V.; Abdi, B.; Teyssou, E.; Soulie, C.; Wirden, M.; Rodriguez, C.; Fourati, S.; Pawlotsky, J.M.; et al. Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers. Clin. Infect. Dis. 2021, in press.

13. Mazzoni, A.; Di Lauria, N.; Maggi, L.; Salvati, L.; Vanni, A.; Capone, M.; Lamacchia, G.; Mantengoli, E.; Spinicci, M.; Zammarchi, L.; et al. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J. Clin. Investig. 2021, 131, e149150. [CrossRef] [PubMed]

14. Gobbi, F.; Buonfrate, D.; Moro, L.; Rodari, P.; Piubelli, C.; Caldiero, S.; Riccetti, S.; Sinigaglia, A.; Barzon, L. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses 2021, 13, 422. [CrossRef] [PubMed]

15. Ebinger, J.E.; Fert-Bober, J.; Printsev, I.; Wu, M.; Sun, N.; Prostko, J.C.; Frias, E.C.; Stewart, J.L.; Van Eyk, J.E.; Braun, J.G.; et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 2021, 27, 981–984. [CrossRef] [PubMed]
31. Soysal, A.; Gönüllü, E.; Karabayır, N.; Alan, S.; Atıcı, S.; Yıldız, İ.; Engin, H.; Çivilibal, M.; Karaböcüoğlu, M. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers. *Hum. Vaccin. Immunother.* 2021, 1–5. [CrossRef]

32. Levi, R.; Azzolini, E.; Pozzi, C.; Ubaldi, L.; Lagioia, M.; Mantovani, A.; Rescigno, M. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19. *J. Clin. Invest.* 2021, 131, e149154. [CrossRef]

33. Moyo-Gwete, T.; Madzivhandila, M.; Makhado, Z.; Ayres, F.; Mhlanga, D.; Oosthuysen, B.; Lambson, B.E.; Kgagudi, P.; Tegally, H.; Iranzadeh, A.; et al. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). *N. Engl. J. Med.* 2021, 384, 2161–2163. [CrossRef]

34. Liu, J.; Liu, Y.; Xia, H.; Zou, J.; Weaver, S.C.; Swanson, K.A.; Cai, H.; Cutler, M.; Cooper, D.; Muik, A.; et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. *Nature* 2021, in press. [CrossRef]

35. Imai, M.; Halfmann, P.J.; Yamayoshi, S.; Iwatsuki-Horimoto, K.; Chiba, S.; Watanabe, T.; Nakajima, N.; Ito, M.; Kuroda, M.; Kiso, M.; et al. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. *Proc. Natl. Acad. Sci. USA* 2021, 118, e2106535118. [CrossRef]

36. Chang, X.; Augusto, G.S.; Liu, X.; Kündig, T.M.; Vogel, M.; Mohsen, M.O.; Bachmann, M.F. BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. *Allergy* 2021. [CrossRef]

37. Wang, P.; Casner, R.G.; Nair, M.S.; Wang, M.; Yu, J.; Cerutti, G.; Liu, L.; Kwong, P.D.; Huang, Y.; Shapiro, L.; et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. *bioRxiv* 2021. [CrossRef]